Navigation Links
Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
Date:12/16/2008

onstrated that the Intermezzo(R) 1.75 mg and 3.5 mg doses, when used at the time of a middle of the night awakening, significantly shortened the time for patients to return to sleep as compared to placebo, with no evidence of next day residual sedative effects with either dose. Further, when patients used the 3.5 mg dose, the study also indicated statistically significant improvements in total sleep time, sleep efficiency, subjective number of post-dose awakenings, sleep quality, level of refreshed sleep, and next day ability to function. Transcept believes that these are the lowest zolpidem doses that have been reported to be statistically superior to placebo in producing sleep.

The second Phase 3 clinical trial was a double-blind, placebo-controlled outpatient study in which 294 patients used either Intermezzo(R) 3.5 mg or placebo at home, at the time they awakened in the middle of the night and had difficulty returning to sleep. This Phase 3 clinical trial also met its primary endpoint of significantly reducing the time required for the patient to return to sleep versus placebo. After dosing and returning to sleep, patients in the outpatient study who were randomized to Intermezzo(R) also reported fewer subsequent awakenings and less time awake during the remainder of the night. There was no evidence of next day residual sedative effects after middle of the night use of Intermezzo(R) versus placebo.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the nigh
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Transcept Pharmaceuticals Appoints Key Senior Executives
3. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual list ... as number 1,361 in growth for the three years through 2014. Being named to ... privately held organizations in the country. , “We are thrilled to make the ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... presented new data on the relationship of genetics and hypertension at the ... Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive ...
(Date:8/26/2015)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... the detection of foodborne pathogens, today announced that Paul ... Company Emerging Growth Conference on September 2 at 9:20am ... York Marriott Marquis. A live webcast ... relations section of Roka Bioscience,s website at http://rokabio.investorroom.com/ ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused ... treatment of immune mediated disease and cancer, today announced that ... 10, at 11:30 a.m. ET at the 8th Annual Needham ... Hotel. , , There will be a live webcast ...
... employees enjoy after work social and pledge drive , , ... Americas Restaurant on The Waterway in ... Oncology, Inc . delighted in an after work social and ... . , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090605/DA28382 ) , ...
... is holding Platoon University at Bryn Mawr Outdoor Fitness Center, from ... MAWR, Pa., June 5 Platoon Fitness is gearing up for ... around the country in its outdoor training methods. , , ... in the realm of outdoor fitness. Over 1100 exercises will be ...
Cached Biology Technology:Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference 2Americas on the Waterway Supports US Oncology Foundation 2Americas on the Waterway Supports US Oncology Foundation 3
(Date:8/24/2015)... South Africa , August 24, 2015 ... Germany ,s largest biometrics manufacturer DERMALOG and its ... with the "2015 African Biometrics Company of the Year Award". ... Nigeria .   -Cross reference: ... http://www.presseportal.de/nr/8896 - On Thursday evening, in ...
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/17/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Q4 2015. The new marketing campaign is being spearheaded ... Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ... in retail driven marketing and brand awareness and has ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... view is that DNA and genes control everything of importance ... thought. , Increasingly, however, scientists are realizing that among the ... from DNA, many interact with each other and with genes ... , In particular, RNA produced by the vast stretches ...
... known as SOS1 account for many cases of Noonan ... in one in 1,000-2,500 live births. NS is ... as well as heart problems and predisposition to leukemia. ... Medical School-Partners Healthcare Center for Genetics and Genomics (HPCGG) ...
... a detrimental effect on a person's ability to recover ... September Journal of Nuclear Medicine. , "Using positron emission ... specific model to study the regenerative capacity of the ... heart's ability to develop new nerves to replace damaged ...
Cached Biology News:Peering into the shadow world of RNA 2Peering into the shadow world of RNA 3Study uncovers mutation responsible for Noonan Syndrome 2Diabetes slows nerve recovery after heart transplant 2
... The Biometra TProfessional Thermocycler combines top ... silver block achieves high speed and unparalleled ... graphical display providing programming in a spreadsheet ... High Performance Smart Lid opens on the ...
...
... Kit is an advanced system for isolating DNA from ... be used directly for any downstream application. ... to use in 56 minutes Low melting point ... and TBE gels No specialised equipment required ...
... Columns provide a rapid and simple method for ... to 10 kb) from stained agarose gels or ... from an agarose gel and loaded into the ... column are a series of membranes and filters ...
Biology Products: